Release Date: October 15, 2025
Expiration Date: October 15, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in neovascular retinal diseases including AMD, DME and RVO. In this educational program, these experts use a case-based format to discuss the latest data regarding management of these disorders and share their perspectives and best practices.
This educational activity is an archive of the live virtual symposium held on August 1, 2025.
The activity is designed to highlight and test participants on the most recent and clinically relevant data in managing neovascular retinal disease with next generation anti-VEGF agents, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
Target Audience
This activity is directed toward retina specialists, comprehensive ophthalmologists, optometrists, and other eye care professionals involved in the treatment of neovascular retinal disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret clinical trial data and real-world evidence supporting the use of next generation anti-VEGF agents for RVO
- Identify patients suitable for extended-interval dosing for nAMD based on baseline characteristics, early fluid response, and real-world insights from recent data.
- Incorporate evidence-based strategies for optimizing extended dosing intervals in the management of DME, minimizing treatment burden, and improving long-term visual outcomes in clinical practice.
SriniVas R. Sadda, MD, FARVO
Director of AI and Imaging Research
Doheny Eye Institute
Professor of Ophthalmology
UCLA
Pasadena, CA
Disclosures: Consultant: 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc. Recipient: Carl Zeiss Meditec, Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc. Financial Support: Carl Zeiss Meditec, Centervue, Heidelberg Engineering, Nidek, Optos Inc., Topcon
Mark R. Barakat, MD, FASRS
Director of Clinical Research Retina Macula Institute of Arizona Clinical Assistant Professor University of Arizona College of Medicine – Phoenix
Phoenix, AZ
Disclosures: Grant/Research Support: Adverum Biotech, Annexon Biosciences, CalciMedica, Clearside Biomedical, Eyebiotech, EyePoint Pharma, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Kanghong/Vanotech, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Perfuse, Regenxbio, ReNeuron, Ribomic, Roche, Stealth Biotherapeutics, Unity Biotechnology; Speakers Bureau: Alcon, Apellis, Astellas, Bausch + Lomb, Genentech, Novartis, Regeneron; Consultant: AbbVie, Adverum Biotech, Alcon, Alimera, Allegro, Allergan, Annexon, Apellis, Arctic Vision, Astellas, Bausch + Lomb, BioCryst, Biogen, Boehringer Ingelheim, CalciMedica, Celltrion, Cencora, Clearside Biomedical, Coherus Biosciences, EyePoint Pharma, Genentech, Kodiak Sciences, Harrow, Janssen, Neurotech, Novartis, Ocular Therapeutix, Oculis, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, Regenxbio, RevOpsis Therapeutics, Roche, Stealth Biotherapeutics; Other: NeuBase, Oxurion, RevOpsis Therapeutics.
David A. Eichenbaum, MD, FASRS
Partner and Director of Research Retina Vitreous Associates of Florida Collaborative Associate Professor Morsani College of Medicine University of South
Florida Tampa, FL
Disclosures: Consultant, Speaker: 4DMT, AbbVie, Adverum, Akari, Amaros, ANI, Annexon, Apellis, Astellas, Bausch + Lomb, Bayer, Bitfount, Boehringer Ingelheim, Complement Therapeutics, CorEvitas/Vestrum, EcoR1, EyePoint, Genentech, Harrow, Kodiak, Kriya, Lexitas, Nanoscope, Neurotech, Notal Vision, Novartis, Ocugen, Ocular Therapeutix, Oculis, Ocuphire, Ollin, Opthea, Orasis, Outlook, Regeneron, Regenxbio, RetinAI, Revive, Roche, Samsara, Stealth, Tilak, Unity; Investigator: 4DMT, Adverum, Aerie/Alcon, Alexion, Allgenesis[KH2.1], Annexon, Astellas, Aviceda, Bayer, Boehringer Ingelheim, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Novartis, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Priovant, Regeneron, Regenxbio, RetinAI, Roche, Samsara, Stealth, Unity Equity/Stockholder/Options: 4DMT, Amaros, Boston Image Reading Center, EyePoint, Hemera, Janssen, Ollin, Revive, US Retina
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here